Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX12 vs Cyramza PK Study in Healthy Males
NCT03863587Phase 1Terminated
- Sponsor
- Henlius
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ramucirumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC) and 2 more (2 arms), sponsored by Henlius. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity at Day 71. Started Jun 2019; status: terminated.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03863587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863587.